Clinical Trials Logo

Filter by:
NCT ID: NCT06321536 Not yet recruiting - Clinical trials for Multi-Drug Resistant Organism Colonization

Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)

Start date: May 2024
Phase: Phase 2
Study type: Interventional

REACT is a phase two, open-label, cluster randomized, crossover study of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.

NCT ID: NCT06321484 Not yet recruiting - Ovarian Cancer Clinical Trials

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The goal of this research study is to evaluate the safety and effectiveness of the use of cytokine-induced memory-like (CIML) natural killer (NK) cell therapy combined with IL-15 superagonist (N-803) in recurrent, high grade ovarian cancer (HGOC). Names of the study therapies involved in this study are: - CIML NK (cellular therapy) - N-803 (a novel immune-cell stimulator)

NCT ID: NCT06321471 Not yet recruiting - Asthma Clinical Trials

AeviceMD for Pediatric Asthma Management

APAM
Start date: March 2024
Phase: N/A
Study type: Interventional

A wearable remote patient monitor (AeviceMD) is to be used to monitor the respiratory health of pediatric asthma patients in this pilot study. Patients prescribed with AeviceMD should be able to gain better control over their disease during home management. Physicians should be able to optimize treatment for these patients using objective data collected from and of these patients outside of the clinic. The AeviceMD should also be used as a remote auscultation device for teleconsultations.

NCT ID: NCT06320990 Not yet recruiting - Pancreatic Cyst Clinical Trials

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

MCN_Tam
Start date: September 2024
Phase: Phase 1
Study type: Interventional

This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic mucinous cystic neoplasms (MCN) who will not undergo immediate resection. Up to 15 participants will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks.

NCT ID: NCT06320951 Not yet recruiting - Obesity Clinical Trials

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

VITAL-IMPACT
Start date: May 1, 2025
Phase: Phase 2
Study type: Interventional

This study investigates the potential of vericiguat, a soluble guanylate cyclase stimulator, to improve cardiometabolic health in obese Black individuals with insulin resistance by directly enhancing cyclic guanosine monophosphate (cGMP) activity. Given that this population has been shown to have lower cGMP activity and the association of lower cGMP activity with increased cardiometabolic disease risk, the proposed study hypothesizes that augmenting cGMP activity in obese individuals will improve insulin sensitivity and energy expenditure. This study is a placebo-controlled randomized trial involving 200 Black obese participants with insulin resistance, assessing the effects of vericiguat on insulin sensitivity, resting, and exercise-induced energy expenditure over 12 weeks. Additionally, it will explore changes in brown adipose tissue and gene expression related to energy metabolism in white adipose tissue, aiming to provide insights into how increasing cGMP activity may improve cardiometabolic health in Black obese individuals.

NCT ID: NCT06320366 Not yet recruiting - Clinical trials for Methamphetamine Use Disorder

Testing an Accelerated TMS Protocol for Methamphetamine Use Disorder

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The investigators will evaluate the effects of an accelerated Transcranial Magnetic Stimulation (TMS) protocol of the left dorsolateral prefrontal cortex (DLPFC) for moderate to severe methamphetamine use disorder. This is a randomized parallel group design to assess feasibility and safety, evaluate efficacy (use, craving) and identify magnetic resonance imaging (resting state and cue craving) associated with group/outcomes.

NCT ID: NCT06319963 Not yet recruiting - Clinical trials for HPV Positive Oropharyngeal Squamous Cell Carcinoma

A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer

Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main questions aim to answer are: - Is Lenti-HPV-07 safe? - Does Lenti-HPV-07 induce an immune response? Participants will be assigned to a group based on their cancer type - either study drug group A: recurrent and/or metastatic cancer - or study drug group B: newly diagnosed with locally advanced cancer After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.

NCT ID: NCT06319872 Not yet recruiting - Clinical trials for Alcohol Use Disorder

The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration

Start date: April 15, 2024
Phase: Phase 1
Study type: Interventional

Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.

NCT ID: NCT06319807 Not yet recruiting - Bottle Feeding Clinical Trials

GrowWell - Responsive Bottle Feeding

Start date: July 2024
Phase: N/A
Study type: Interventional

The overall goal of this research is use digital health to augment the clinical encounter with Women, Infants, and Children (WIC) clinicians and prevent rapid infant weight gain among children living in low-income households. Intervening on weight gain during infancy offers an opportunity to influence lifelong obesity risk. Using personalized motivational messages and targeted skills-training resources, the intervention will support parents and caregivers in adopting responsive feeding strategies. Knowledge gained from this project will be used to develop a future, larger grant submission focused on developing healthy feeding and eating habits among mother-infant dyads.

NCT ID: NCT06319716 Not yet recruiting - Type 2 Diabetes Clinical Trials

Leveraging Videos and Community Health Workers to Address Social Determinants of Health in Immigrants

LINK-IT
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The overall goal of this study is to examine the efficacy of the video-based Diabetes Self-Management Education and Support (DSMES) (hereafter VIDEO), or the video-based DSMES+community health worker (CHW) intervention (hereafter VIDEO+CHW), compared with a wait-list control group (hereafter CONTROL) to improve glycemic control among Chinese immigrants with uncontrolled Type 2 diabetes in NYC.